Meta-analysis Of Hyperthermic Intraperitioneal Chemotherapy Combined With Intravenous Chemotherapy For Advanced Ovarian Cancer

Objective To evaluate the efficacy and safety of hyperthermic intraperitioneal chemotherapy(HIPEC)combined with intravenous chemotherapy in the treatment of advanced ovarian cancer,and provide reference for clinical research and application.Method A computer-based search of PUBMED,VLP,CNKI,and Wanfang database to collect all randomized controlled trials comparing hyperthermic intraperitioneal chemotherapy(HIPEC)with intravenous systemic chemotherapy and simple intravenous systemic chemotherapy(IC)for advanced ovarian cancer.(RCT),the search time limit is from the establishment of the library to June 2018.Meta-analysis was performed using Rev Man 5.2 software after independently screening the literature,extracting data,and evaluating quality according to inclusion and exclusion criteria.Results A total of 12 RCTs and 798 patients were included.Meta-analysis results showed that the HIPEC group was clinically effective [RR=1.53,95%CI(1.34,1.75),P<0.00001],ascites control rate [RR=1.55,95% CI(1.27,1.88),P<0.00001 The aspects were significantly better than the IC group,and the difference was statistically significant.In terms of safety,the incidence of myelosuppression in the HIPEC group[RR=1.55,95% CI(1.27,1.88),P<0.00001] was significantly lower than that in the IC group,and the difference was statistically significant.There was no significant difference in 1-year survival rate,incidence of liver and kidney dysfunction,and incidence of nausea and vomiting(P>0.05).Conclusions hyperthermic intraperitioneal chemotherapy combined with intravenous chemotherapy for advanced ovarian cancer can improve the clinical efficiency,ascites control rate,and safety,but there is no significant difference in 1-year survival rate.